Matthew McIntyre, MD
Urology · Mobile, ALNPI 1659450666
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,758 of the $6,061 with a category attached, or 62.0%. 34 manufacturers reported payments, led by Cornerstone Urology Network, LLC at 43.9% of the total. 2025 is the largest year on record at $3,198, 5.8 times the $555 reported in 2019.
Across 167 payments — averaging $36.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cornerstone Urology Network, LLC$3K
- Astellas Pharma US Inc$543
- Johnson & Johnson$396
- Boston Scientific$303
- Pfizer$249
- Medtronic$215
- plus $2K from 28 others
Across 1 payment — averaging $20,650 each. An ownership or investment interest held by the physician or an immediate family member.
- Cornerstone Urology Network, LLC$21K
What the payments were for
- Travel & lodging$2,10435%
- Food & beverage$3,75862%
- Education$1993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cornerstone Urology Network, LLC | 3 | $2,660 |
| Astellas Pharma US Inc | 30 | $543 |
| Johnson & Johnson(2 entities) | 24 | $396 |
| Boston Scientific | 11 | $303 |
| Pfizer | 16 | $249 |
| Medtronic | 7 | $215 |
| Dendreon Pharmaceuticals LLC | 6 | $215 |
| Urogen Pharma, Inc. | 12 | $214 |
| Sumitomo Pharma America, Inc. | 9 | $159 |
| Procept Biorobotics Corporation | 2 | $93 |
| Axonics, Inc. | 3 | $90 |
| AbbVie(2 entities) | 6 | $85 |
| Bayer | 3 | $84 |
| Coloplast | 3 | $82 |
| Endo Pharmaceuticals Inc. | 4 | $79 |
| Urovant Sciences Inc | 4 | $75 |
| Antares Pharma, Inc. | 3 | $60 |
| Blue Earth Diagnostics | 1 | $56 |
| Intuitive Surgical | 1 | $52 |
| Tolmar Pharmaceuticals, Inc. | 3 | $50 |
| Baxter Healthcare | 2 | $36 |
| Accord Healthcare, Inc. | 2 | $34 |
| Neotract Inc. | 1 | $29 |
| Novartis | 1 | $27 |
| Olympus America Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $24 |
| Innovation Technologies Inc | 1 | $23 |
| Photocure Inc | 1 | $22 |
| Rochester Medical Corporation | 1 | $16 |
| Mission Pharmacal Company | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
| Halozyme Inc | 1 | $13 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,061 in reported general payments places this provider in the 70th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 64 | $170,986 |
| MyrbetriqMirabegron | 103 | $54,551 |
| GemtesaVibegron | 75 | $50,930 |
| Tamsulosin Hcl | 597 | $7,788 |
| Methenamine Hippurate | 69 | $5,075 |
| Testosterone Cypionate | 104 | $4,697 |
| Cabergoline | 48 | $4,647 |
| Duloxetine Hcl | 160 | $4,121 |
| Testosterone | 18 | $3,596 |
| Oxybutynin Chloride ErOxybutynin Chloride | 167 | $3,449 |
| Silodosin | 15 | $1,735 |
| Oxybutynin Chloride | 70 | $1,662 |
| Finasteride | 126 | $1,500 |
| Estradiol | 19 | $1,479 |
| Tolterodine Tartrate ErTolterodine Tartrate | 24 | $1,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $159 | $221,916139 claims |
| Astellas Pharma US IncMyrbetriq | $543 | $54,551103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 179 urology providers in Alabama.
Other urology in Mobile
- Lorie FleckMobile$26K
- Zachary ReardonMobile$19K
- Ted KleinMobile$18K
- Austin YoungerMobile$18K
- William BlaylockMobile$13K
- Guy OswaltMobile$9K
- Kristie Blanchard-BurchMobile$8K
- Paul ScottMobile$8K
- William SandersonMobile$7K
- Robert HelmMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.